Menu Search
Equities

Biovaxys Technology Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BVAXF:QBB

Biovaxys Technology Corp

Actions
  • Price (USD)0.0933
  • Today's Change0.001 / 1.30%
  • Shares traded750.00
  • 1 Year change-73.79%
  • Beta0.7161
Data delayed at least 15 minutes, as of Feb 18 2026 14:32 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergies, and other immunological diseases. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers and also delivers an innate immune activator and a universal CD4 T cell helper peptide.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-6.04m
  • Incorporated2018
  • Employees--
  • Location
    Biovaxys Technology Corp146 Thirtieth Street, Suite 100TORONTO M8W 3D4CanadaCAN
  • Phone+1 (604) 262-8835
  • Fax+1 (604) 262-8835
  • Websitehttps://www.biovaxys.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.